Payment overview · 2025
General Payments
$241.57
4 reported records · 4 companies
Healthcare provider profile · identity verified
Amy E Robertson, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · POPLAR BLUFF, MO · NPI 1881667269
Verified facts
What the public records show
CMS Open Payments records show Amy E Robertson, FNP received $241.57 in general payments during 2025 across 4 reported records.
Medtronic, Inc. accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$117.50 | 48.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $84.99 | 35.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.32 | 10.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.76 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $117.50 | 1 |
| Education | $84.99 | 1 |
| Food and Beverage | $39.08 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $117.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 361 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 74 |
| Lisinopril | Lisinopril | 249 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 62 |
| Gabapentin | Gabapentin | 227 | 61 |
| Montelukast Sodium | Montelukast Sodium | 198 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 58 |
| Potassium Chloride | Potassium Chloride | 192 | 37 |
| Losartan Potassium | Losartan Potassium | 180 | 44 |
| Famotidine | Famotidine | 172 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 45 |
| Metformin Hcl Er | Metformin Hcl | 154 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 34 |
| Furosemide | Furosemide | 138 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 41 |
| Buspirone Hcl | Buspirone Hcl | 125 | 24 |
| Celecoxib | Celecoxib | 116 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 105 | 24 |
| Trazodone Hcl | Trazodone Hcl | 98 | 23 |
| Metformin Hcl | Metformin Hcl | 85 | 24 |
| Glimepiride | Glimepiride | 80 | 24 |
| Memantine Hcl | Memantine Hcl | 77 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 76 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 15 |
| Meloxicam | Meloxicam | 74 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 17 |
| Simvastatin | Simvastatin | 71 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 21 |
| Ozempic | Semaglutide | 64 | 13 |
| Donepezil Hcl | Donepezil Hcl | 63 | 15 |
| Eliquis | Apixaban | 62 | suppressed |
| Trulicity | Dulaglutide | 62 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 61 | suppressed |
| Ibuprofen | Ibuprofen | 61 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 24 |
| Azithromycin | Azithromycin | 58 | 43 |
| Prednisone | Prednisone | 58 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 12 |
| Methylprednisolone | Methylprednisolone | 54 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Ezetimibe | Ezetimibe | 51 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Bupropion Xl | Bupropion Hcl | 44 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 18 |
| Allopurinol | Allopurinol | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | 11 |
| Naproxen | Naproxen | 35 | 11 |
| Topiramate | Topiramate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 21 |
| Hydrocortisone | Hydrocortisone | 25 | 11 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Roflumilast | Roflumilast | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Febuxostat | Febuxostat | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | 13 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Baclofen | Baclofen | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Flavoxate Hcl | Flavoxate Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $241.57 · 4 records | Medtronic, Inc. | COREVALVE EVOLUT R, GEMTESA, Ozempic, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error